

Flexible 1-[(2-Aminoethoxy)alkyl]-3-ar(o)yl(thio)ureas as Novel Acetylcholinesterase Inhibitors. Synthesis and Biochemical Evaluation

Jean-Louis Vidaluc,^{*,†} Francis Calmel,[†] Dennis C. H. Bigg,^{†,§} Elisabeth Carilla,[‡] and Mike Briley[‡]

Divisions of Medicinal Chemistry and Neurobiology, Centre de Recherche Pierre Fabre, 17, avenue Jean Moulin, 81106 Castres Cedex, France

Received August 3, 1994[®]

A series of flexible 1-(2-aminoethoxy)-3-ar(o)yl(thio)ureas was synthesized and assessed for antiacetylcholinesterase activity. This series was designed in order to optimize the spacer length linking the two pharmacophoric moieties, i.e., the basic nitrogen and the ar(o)yl(thio)urea unit, and to test compounds with greater conformational flexibility. Thus, the replacement of the previously described spacer, 4-piperidinyethyl, by a linear ethoxyethyl chain gave compounds of slightly comparable potency, providing that they were correctly substituted. The results show that this new flexible spacer is compatible with high inhibitory activities. The optimal chain length corresponds to five methylene groups, allowing an efficient interaction between the two pharmacophoric units and the two reported hypothetical enzyme hydrophobic binding sites. Moreover, the initially optimized benzyl group, attached to the basic nitrogen, was found to be advantageously replaced by a cyclohexyl group, showing that an aromatic residue does not represent a prerequisite for activity.

Introduction

Alzheimer's disease has become a major health care problem, affecting mainly the industrialized nations with aging populations. The NIH projections (see ref 17) for the year 2000 reveals that 5–8 million Americans could be affected, corresponding to a worldwide patient population of about 24 million people. The market consequences could reach \$2 billion for the treatment, and \$325 million for the diagnosis of the disease, the whole being estimated to at least \$6 billion by the year 2007.


The rational treatment of this challenging neurodegenerative disease must take into account at least four main problems: (1) efficient diagnosis during a postulated reversible phase of the disease, (2) the understanding of the relevant underlying biochemical processes, (3) the definition and choice of appropriate targets, and (4) the design of potent and selective molecules directed to these targets.

Acetylcholinesterase (AChE) inhibition belongs to the cholinergic replacement strategy designed for compensation of the primary selective degeneration of cholinergic neurons.¹ This target requires functional cholinergic neurons and is thus only applicable to the early stages of the disease. The observed clinical efficiency of AChE inhibitors such as physostigmine, tacrine,² and, more recently, Huperzine A³ and E-2020,⁴ despite some controversial results, strengthens this hypothesis.

Structural polymorphism of AChE, associated with its noncholinergic actions, were recently suggested⁵ and then demonstrated.⁶ In certain pathological conditions, including Alzheimer's disease, AChE was found to exist as several isoforms, some of which have been reported to act as proteases.⁷

The intense research devoted to the understanding the biochemical processing of APP and to the accumula-

Chart 1





tion of β A4-amyloid protein (β AP) in the cerebral cortex suggested the action of an unknown protease of the chymotrypsin-like type.⁸ Moreover, the evidence of a colocalization^{9a} of AChE and β AP led to the hypothesis that the "abnormal"^{9b} processing of APP could be due to the proteolytic action of at least one of the pathological isoforms of AChE. A unifying hypothesis was recently reported^{9c} as a model for β -amyloid aggregation and neurotoxicity based on free radical generation by the peptide. Thus, possibly, AChE inhibitors could act in a convergent manner: first, as a classical replacement strategy in providing a normal level of acetylcholine in the synaptic cleft; second, as potential inhibitors

^{*} Division of Medicinal Chemistry.

[†] Division of Neurobiology.


[‡] Present address: Department of Organic Chemistry, Institut Henri Beaufour, 17, avenue Descartes, 92350 Le Plessis Robinson, France.

[®] Abstract published in *Advance ACS Abstracts*, June 15, 1995.

Scheme 1^a**Method B**

^a (a) KI, DMF, 100 °C; (b) R₁R₂NH, DMF, 100 °C, 8 h; (c) NH₂NH₂·H₂O, EtOH, reflux, 3 h; (d) H₂C=CHCN, EtONa, 80 °C, 7 h; (e) H₂, Raney Ni, EtOH-NH₄OH.

Scheme 2



of the production of β AP which leads to the formation and accumulation of the senile plaques.

Most known and newly reported^{10a} AChE inhibitors are rigid, as illustrated by tacrine, physostigmine, huperzine A, and galanthamine (see Chart 1), or at least conformationally restrained as represented by E-2020 and compounds that we recently described.^{10c} Flexible compounds still remain a rare structural class among the AChE inhibitors. However, a number of flexible molecules have been reported to behave as "molecular chameleons", i.e., to adapt their polarity to that of the medium.¹¹ The resulting different conformations could display variable ability to cross hydrophobic cell membranes, thus generating compounds with potential centrally selective bioavailability.

In order to assess the importance of the previously reported conformationally restrained piperidine¹² linker on AChE inhibitory activity, we now describe the synthesis and biochemical evaluation of a series of flexible new 1-[(2-aminoethoxy)alkyl]-3-ar(o)yl(thio)ureas derivatives related to compounds **8**^{10b,c} (Chart 1) as acetylcholinesterase inhibitors.

Chemistry

The described structures were prepared by classical methods as shown in Schemes 1 and 2. 2-Aminoethoxy


ethers **3** were synthesized by a standard Gabriel sequence starting from the commercially available bis(2-chloroethyl) ether (method A). In the case of amino-propoxy ethers **5**, a base-catalyzed Michael addition of 2-aminoethanols to acrylonitrile was used, followed by catalytic hydrogenation of the resulting β -cyano ethers **4** (method B). Compounds **6** and **7** were obtained, as described in our previous paper,^{10c} by reaction of the above amino ethers **3** and **5** with the appropriate ar(o)-yliso(thio)cyanates (Scheme 2).



Structure-Activity Relationships

This series was designed to test the opportunity of inserting a linear spacer between a basic nitrogen and the pharmacophoric ar(o)yl(thio)urea moiety in order to enhance molecular flexibility. The direct comparison of **8a** (see Chart 1) and its flexible analog **6a** showed a lower affinity for the latter (see Table 1). In most cases classical substitution of the aromatic ring with polar R₃ and R₄ groups led to enhanced inhibitory activities for the substituted compounds versus the parent compound **6a**, as shown in Table 1. The highest activities were observed for the 3-nitro derivative **6e** and for **6j** as was reported for the piperidine series.^{10c}

A comparison of **6c** (or **6d**) and **6a** showed that a 4-methoxy (or 4-chloro) substitution resulted in a 4-fold


Table 1. Aroylthiourea Derivatives



no.	R1	R2	n	R3	R4	yield, ^e %	mp, ^a °C	formula	IC ₅₀ of AChE inh, nM ^d
6a	C ₆ H ₅ CH ₂	Me	1	H	H	44	116–8	C ₂₆ H ₂₆ ClN ₃ O ₂ S	120 [13] ^f
6b	C ₆ H ₅ CH ₂	Me	1	4-Me	H	48	152–3 ^b	C ₂₈ H ₃₁ N ₃ O ₆ S	77
6c	C ₆ H ₅ CH ₂	Me	1	4-OMe	H	39	140–2	C ₂₁ H ₂₈ ClN ₃ O ₃ S	26 [10] ^f
6d	C ₆ H ₅ CH ₂	Me	1	4-Cl	H	40	150–1 ^b	C ₂₄ H ₂₆ ClN ₃ O ₆ S	30 [20] ^f
6e	C ₆ H ₅ CH ₂	Me	1	3-NO ₂	H	35	94–6 ^b	C ₂₄ H ₂₈ N ₄ O ₉ S	15 [1.5] ^f
6f	C ₆ H ₅ CH ₂	Me	1	3-Cl	4-Cl	52	123–4 ^b	C ₂₄ H ₂₇ Cl ₂ N ₃ O ₆ S	55
6g	C ₆ H ₅ CH ₂	Me	1	4-Ph	H	35	130–2	C ₂₆ H ₃₀ ClN ₃ O ₂ S	230
6h	C ₆ H ₅ CH ₂	Me	1	3,4-benzo		45	202–4	C ₂₄ H ₂₈ ClN ₃ O ₂ S	100
6i	C ₆ H ₅ CH ₂	Me	1			22	205–10	C ₂₇ H ₂₈ ClN ₃ O ₂ S	30 [80] ^f
6j	C ₆ H ₅ CH ₂	Me	1			21	132–4 ^b	C ₃₂ H ₃₁ N ₃ O ₈ S	6 [2] ^f
6k	C ₆ H ₅ CH ₂	Me	2	H	H	26	98–100 ^b	C ₂₅ H ₃₁ N ₃ O ₆ S	1100
6l	c-C ₆ H ₁₁	Me	1	H	H	44	141–2 ^c	C ₂₁ H ₃₁ N ₃ O ₄ S ^{4f}	13

^a All melting points refer to hydrochlorides unless otherwise indicated. ^b Fumarate. ^c Hemifumarate. ^d The IC₅₀ values for AChE inhibition were estimated graphically from log concentration/% inhibition curves of 6–15 values. ^e Yields refer to isolated, analytically pure bases. ^f Slightly off value of carbon analysis. ^g Values of the corresponding piperidine analogues^{10c} are shown in brackets. (Compound **8a** [13 nM], shown in Chart 1, is the corresponding piperidine analog of **6a**.)

Table 2. Aryl(thio)urea Derivative



no.	R1	R2	X	R3	yield, ^e %	mp, °C	formula	IC ₅₀ of AChE inh, nM ^d
7a	C ₆ H ₅ CH ₂	Me	S	4-chlorophenyl	50	134–5 ^a	C ₁₉ H ₂₅ Cl ₂ N ₃ O ₅ S ^f	1800
7b	C ₆ H ₅ CH ₂	Me	S	1-naphthyl	64	116–7 ^c	C ₂₃ H ₂₇ N ₃ O ₅ S	> 10000
7c	3-NO ₂ -PhCH ₂	Me	S	3,4-dimethoxyphenyl	61	118–25 ^a	C ₂₁ H ₂₅ ClN ₄ O ₅ S	1500
7d	C ₆ H ₅ CH ₂	Me	S	4-(trifluoromethoxy)phenyl	33	142–3 ^a	C ₂₀ H ₂₅ F ₃ ClN ₃ O ₅ S	1000
7e	C ₆ H ₅ CH ₂	Me	S	3-pyridyl	56	70–90 ^b	C ₂₂ H ₂₇ N ₅ O ₇ S	4000 [500] ^f
7f	C ₆ H ₅ CH ₂	Me	S	cyclohexyl	64	132–4 ^b	C ₁₉ H ₃₂ ClN ₃ O ₅ S	1400
7g	c-C ₆ H ₁₁ CH ₂	Et	O	C ₆ H ₅ CH ₂	49	66–7 ^c	C ₂₀ H ₃₃ N ₃ O ₂	> 10000
7h	C ₆ H ₅ CH ₂	Me	O	4-nitrophenyl	82	176–7 ^a	C ₁₉ H ₂₅ ClN ₄ O ₄	2300

^a Hydrochloride. ^b Fumarate. ^c Free base. ^d See note d of Table 1. ^e Yields refer to isolated, analytically pure bases. ^f Slightly off value of carbon analysis. ^g Value of the corresponding piperidine analog.

increase in affinity; this fact was not observed in the piperidine series. In contrast, the 8-fold increase in potency of **6e** versus **6a** is also observed by comparing the piperidine analogs (see Table 1). The potential interest in the flexible compounds was especially shown by compound **6i** which displayed a significantly better potency than its more strained analog.

The above results may be explained in terms of a different (better in the case of **6i**) ability of flexible compounds to adapt their molecular shape to that of the active site of the enzyme.

The elongation by one carbon atom of the chain of **6a** resulted in a 10-fold decrease in potency as shown by compound **6k**. The optimum spacer was observed for $n = 1$, which was similar in length to that reported in the piperidine series.

Interestingly, the replacement of the standard benzyl group in **6a** by a cyclohexyl unit in **6l** resulted in a substantially higher activity which contrasts with data reported elsewhere.^{13a–f} Thus, the initial view of the necessity of a benzyl substituent at the basic nitrogen appeared to be unfounded.

The series of the aryl(thio)urea derivatives (compounds **7**, Table 2) showed a 10-fold global loss of potency compared to the aroyl(thio)ureas. No real interest was raised by classical substitution of the phenyl ring.

In conclusion, the flexible aroylthiourea derivatives **6**, with a linear (2-aminoethoxy)ethyl spacer, proved to be as potent AChE inhibitors as the conformationally more restrained reference compounds such as E-2020 or **8a** (**8a** corresponds to compound **7a** of our previous study^{10c}); they can show even better inhibitory activities than the highly strained reference compounds (Table 3). Replacement of a benzyl group by a cyclohexyl group on the basic nitrogen resulted in a 10-fold better activity, showing that an aromatic residue does not represent a prerequisite for efficiency. In contrast, the linear (thio)urea derivatives **7** were 10-fold less active than their piperidine analogs.

Experimental Section

All melting points were determined on a Kofler apparatus and are uncorrected. ¹H NMR spectra were recorded using a

Table 3. Reference Values in AChE Inhibition

reference compounds	IC ₅₀ of AChE inh, nM	
	observed	reported
physostigmine	80 ± 3.4 ^a	0.68 ± 0.02 ^{d, 12d}
galanthamine	538 ± 60 ^a	360 ¹⁶
tacrine	63 ± 1.3 ^a	80.6 ± 2.5 ^{12d}
huperzine A	nd ^b	100 ^{3e}
E-2020	17 ± 5.0 ^a	5.7 ± 0.2 ^{12d}
8a ^e	13 ^{c, 10}	

^a These values represent the mean ± SE from four dose-response curves for each reference compound. ^b nd = not determined. ^c This value was estimated graphically from log *C*/*I* inhibition curves of five experiments. ^d Differences frequently observed in the reported values for physostigmine are a consequence of its short half-life and variations in the time of observation. ^e This compound **8a** (see Chart 1) corresponds to compound **7a** of our previous paper.^{10c} (It corresponds to the piperidine analog of **6a** of the present paper.)

Bruker AC-200 spectrometer using Me₄Si as an internal standard. Elemental analyses are indicated only by the symbols of the elements; analytical results were within 0.4% of the theoretical values unless otherwise noted.

2-[2-(2-Chloroethoxy)ethyl]-1*H*-isoindole-1,3(2*H*)-dione (1). This versatile compound was first synthesized using a procedure described by Cretcher and collaborators and recently modified by Calderon and collaborators.¹⁴ We report here our conditions involving an excess of bis(2-chloroethyl) ether in hot DMF which led to better yields. To a solution of bis(2-chloroethyl) ether (23 g, 0.161 mol) in DMF (100 mL) at 100 °C were successively added KI (50.0 mg, 0.30 mmol) and potassium phthalimide (10.0 g, 54.0 mmol) portionwise over 1 h. The resulting brown-yellow suspension was stirred for a further 2 h, allowed to cool to room temperature, poured into 200 mL of H₂O, and extracted with CH₂Cl₂. The organic phase was washed, dried over Na₂SO₄, and evaporated to leave an orange oil. This was purified by silica gel column chromatography (hexane–AcOEt, 1:1) to give 11.0 g (80.3%) of white crystals of **1**: mp 69–70 °C; ¹H NMR (CDCl₃) δ 3.50–3.56 (t, 2H), 3.68–3.77 (m, 4H), 3.85–3.91 (t, 2H), 7.66–7.71 (m, 2H), 7.78–7.84 (m, 2H).

2-[2-(2-(*N*-Benzyl-*N*-methylamino)ethoxy)ethyl]-1*H*-isoindole-1,3(2*H*)-dione (2a). To a stirred solution of *N*-methylbenzylamine (6.45 mL, 50.0 mmol) in 15 mL of DMF was added dropwise a solution of **1** (6.34 g, 25.0 mmol) in 20 mL of DMF. The mixture was stirred at 100 °C for 8 h, poured into 300 mL of H₂O, and extracted with AcOEt. The organic phase was washed with water and brine, dried over Na₂SO₄, and evaporated to give a yellow oil which was purified by silica gel column chromatography (CHCl₃, then CHCl₃–MeOH, 95:5) to give 7.4 g (87.5%) of **2a** as a yellow oil: ¹H NMR (CDCl₃) δ 2.15 (s, 3H), 2.52–2.58 (t, 2H), 3.46 (s, 2H), 3.55–3.69 (m, 4H), 3.83–3.89 (t, 2H), 7.15–7.27 (m, 5H), 7.62–7.69 (m, 2H), 7.73–7.79 (m, 2H).

2-[2-(*N*-Benzyl-*N*-methylamino)ethoxy]ethanamine (3a). To a stirred solution of **2a** (4.90 g, 14.5 mmol) in 50 mL of EtOH was added hydrazine hydrate (1.40 mL, 28.8 mmol). The mixture was heated at reflux with stirring for 3 h (after around 30 min, white crystals formed). The mixture was filtered, the precipitate rinsed with EtOH, and the filtrate evaporated to dryness. The resulting yellow oily residue was taken up in 2 N HCl, stirred for 5 min at 50 °C, then basified with 2 N NaOH, and extracted with CHCl₃. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, and evaporated to dryness to leave 2.02 g (67.0%) of **3a** as a yellow oil which was used for the next step without further purification: ¹H NMR (CDCl₃) δ 2.26 (s, 3H), 2.58–2.64 (t, 2H), 2.78–2.87 (m, 4H), 3.45–3.61 (m, 6H), 7.23–7.32 (m, 5H).

2-[2-(*N*-Benzyl-*N*-methylamino)ethoxy]propionitrile (4a). A suspension of *N*-benzyl-*N*-methyl-2-ethanolamine (16.52 g, 10 mmol), acrylonitrile (5.57 g, 10.5 mmol), and sodium ethoxide (0.55 g, 10.2 mmol) was heated at 80 °C with stirring for 7 h. After cooling to room temperature, the dark brown mixture was poured into H₂O and extracted with CH₂-

Cl₂. The organic phase was washed with water and brine, dried over Na₂SO₄, and filtered and the solvent evaporated. The resulting brown oily residue was purified by silica gel column chromatography (AcOEt, then AcOEt–MeOH, 95:5) to leave 16.75 g (76.7%) of **4a** as a brown oil: ¹H NMR (CDCl₃) δ 2.30 (s, 3H), 2.56–2.67 (m, 4H), 3.58 (s, 2H), 3.60–3.68 (m, 4H), 7.25–7.34 (m, 5H).

3-[2-(*N*-Benzyl-*N*-methylamino)ethoxy]propanamine (5a). To a solution of **4a** in EtOH (50 mL), H₂O (40 mL), and NH₄OH (20 mL) was added Raney Ni catalyst (1.5 g). The atmosphere above the mixture was successively purged with nitrogen and hydrogen and then stirred vigorously at room temperature until 2.8 L of H₂ was adsorbed. The catalyst was removed by filtration using a Whatman glass microfibre filter and the filtrate evaporated to dryness. The residual oil was treated with brine and extracted with AcOEt; the organic phase was dried over Na₂SO₄ and evaporated to dryness to leave 15.7 g of an oily yellow residue which was purified by silica gel column chromatography (CHCl₃–MeOH–NH₄OH, 90:10:1) to give 10.0 g (70.4%) of a pale oil of **5a**: ¹H NMR (CDCl₃) δ 1.61 (s, 2H), 1.63–1.76 (q, 2H), 2.25 (s, 3H), 2.56–2.62 (t, 2H), 2.74–2.81 (t, 2H), 3.45–3.57 (m, 6H), 7.22–7.31 (m, 5H).

1-Benzoyl-3-[1-[2-[2-(*N*-benzyl-*N*-methylamino)ethoxy]ethyl]thiourea (6a). To a well-stirred suspension of finely powdered KSCN (0.9 g, 9.26 mmol) in 20 mL of dry acetone under nitrogen was added dropwise benzoyl chloride (1.2 mL, 10.34 mmol) in 5 mL of acetone. The immediately obtained white suspension was stirred under reflux for 5 min. Then a solution of **3a** (2.0 g, in 5 mL) in CH₂Cl₂ was added, and the resulting orange suspension was allowed to cool to room temperature for 1 h. The solvents were evaporated, H₂O was added to the residue, and the mixture was extracted with CHCl₃. The organic phase was washed, dried over Na₂SO₄, and evaporated to leave an orange gummy residue which was purified by silica gel column chromatography (CHCl₃, then CHCl₃–MeOH, 95:5) to give 1.55 g (43.4%) of **6a** as an orange gum: ¹H NMR (CDCl₃) δ 2.31 (s, 3H), 2.69–2.75 (t, 2H), 3.63 (s, 2H), 3.67–3.74 (m, 4H), 3.90–3.97 (q, 2H), 7.21–7.37 (m, 5H), 7.47–7.67 (m, 3H), 7.79–7.84 (d, 2H), 9.02 (bs, 1H), 10.94 (bs, 1H). Anal. (C₂₀H₂₆ClN₃O₂S) C, H, N, Cl, S (hydrochloride).

1-Cyclohexyl-3-[1-[2-[2-(*N*-benzyl-*N*-methylamino)ethoxy]ethyl]thiourea (7f). To a stirred solution **3a** (3.6 g, 17.3 mmol) in 50 mL of CH₂Cl₂ was added dropwise a solution of cyclohexyl isothiocyanate (2.43 g, 17.3 mmol) in 10 mL of CH₂Cl₂. The mixture was allowed to stir at room temperature for 1 h. The solvent was removed and the resulting yellow oily residue purified by silica gel column chromatography (AcOEt–MeOH, 95:5) to give 3.87 g (64.1%) of the title product as an oily base which was converted to its hydrochloride with HCl–EtOH in Et₂O to give 2.35 g (39.0%) of **7f** as white crystals: mp 132–4 °C; ¹H NMR (CDCl₃) δ 1.10–1.71 (m, 9H), 1.99–2.01 (m, 2H), 2.87–2.89 (ds, 3H), 2.90–3.01 (m, 1H), 3.28–3.38 (m, 1H), 3.59–3.71 (m, 6H), 3.88–3.96 (m, 1H), 3.98–4.15 (m, 2H), 4.49–4.57 (dd, 1H), 7.45–7.50 (m, 3H), 7.58–7.63 (m, 2H), 11.08 (bs, 1H). Anal. (C₁₉H₃₂ClN₃OS) C, H, N, Cl, S.

Materials and Methods. Determination of Acetylcholinesterase Activity. The in vitro inhibitory effects of the various compounds on acetylcholinesterase activity were determined spectrophotometrically by the method of Ellman et al.¹⁵ using homogenates of rat forebrain.

Acknowledgment. We thank Mr. Michel Barrau and Dr. Jean-Paul Ribet from the Analytical Chemistry Department of Pierre Fabre Research Center for providing NMR spectra and elemental analysis data, Miss Evelyne Manibe for technical contribution, Mr. Michel Marbach for in vitro biological experiments, and Miss Caroline Beyt for the drawings and secretarial assistance.

References

- (1) (a) Davies, P.; Maloney, A. J. F. Selective loss of central cholinergic neurons in Alzheimer's disease. *Lancet* **1976**, No. 2, 1403. (b) Wurtman, R. J. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. *Trends Neurosci.* **1992**, *15* (4), 117-22. (c) Galdzicki, Z.; Fukuyama, R.; Wadhvani, K. C.; Rapoport, S. J.; Ehrenstein, G. β -Amyloid increases choline conductance of PC12 cells: Possible mechanism of toxicity in Alzheimer's disease. *Brain Res.* **1994**, *646* (2), 332-6.
- (2) (a) Summers, W. K.; Majovski, L. V.; Marsh, G. M.; Tachiki, K.; Kling, A. Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. *N. Engl. J. Med.* **1986**, *315*, 1241. (b) Farlow, M. J. *Am. Med. Assoc.* **1992**, *268*, 2523.
- (3) (a) Zhang, S. L. *New Drugs Clin. Rem.* **1986**, *5* (5), 260. (b) Cheng, Z. S.; et al. *New Drugs Clin. Rem.* **1986**, *5* (4), 197. (c) Tang, X.-C.; De Sarno, P.; Sugaya, K.; Giacobini, E. *J. Neurosci. Res.* **1989**, *24*, 276-85. (d) *Drugs Future* **1987**, *12* (6), 531-2; **1988**, *13* (6), 575; **1989**, *14* (6), 575; **1990**, *15* (6), 626-7; **1991**, *16* (6), 577; **1992**, *17* (6), 518-9; **1993**, *18* (6), 574. (e) Kozikowski, A. P.; Xia, Y.; Reddy, E. R.; Tückmantel, W.; Hanin, I.; Tang, X. C. Synthesis of Huperzine A and Its Analogues and Their Anticholinesterase Activity. *J. Org. Chem.* **1991**, *56* (15), 4636-45.
- (4) (a) Sherman, K. A. Effect of oral administration of reversible inhibitors on blood acetylcholinesterase in humans: Tacrine and E-2020. *Soc. Neurosci. Abst.* **1991**, *17* (Part 2), Abst 488.11. (b) *Drugs Future* **1991**, *16* (1), 16-8; **1992**, *17* (1), 56; **1993**, *18* (1), 77-8.
- (5) (a) Greenfield, S. Acetylcholinesterase may have novel functions in the brain. *Trends Neurosci.* **1984**, *7*, 364-8. (b) Balasubramanian, A. S. Have cholinesterases more than one function? *Trends Neurosci.* **1984**, *7*, 467-8. (c) Small, D. H. Non-cholinergic actions of acetylcholinesterases: proteases regulating cell growth and development? *Trends Biochem. Sci.* **1990**, 213-6.
- (6) (a) Michaelson, S.; Small, D. H. A protease is recovered with a dimeric form of acetylcholinesterase in fetal bovine serum. *Brain Res.* **1993**, *611*, 75-80. (b) Balasubramanian, A. S.; Bhanumathy, C. D. Noncholinergic functions of cholinesterases. *FASEB J.* **1993**, *7* (14), 1354-8. (c) Appleyard, M. E. Non-cholinergic functions of acetylcholinesterase. *Biochem. Soc. Trans.* **1994**, *22* (3), 749-55.
- (7) (a) Navaratnam, D. S.; Priddle, J. D.; McDonald, B.; Esiri, M. M.; Robinson, J. R.; Smith, A. D. Anomalous molecular form of acetylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease. *Lancet* **1991**, *337*, 447-50. (b) Small, D. H.; Moir, R. D.; Fuller, S. J.; Michaelson, S.; Bush, A. I.; Li, Q. X.; Milward, E.; Hilbich, C.; Weidemann, A.; Beyreuther, K.; Masters, C. L. A protease Activity Associated with Acetylcholinesterase Releases the Membrane-Bound Form of the Amyloid Protein Precursor of Alzheimer's Disease. *Biochemistry* **1991**, *30*, 10795-9. (c) Ogane, N.; Giacobini, E.; Struble, R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. *Brain Res.* **1992**, *589*, 307-12. (d) Appleyard, M. E. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. *Trends Neurosci.* **1992**, *15* (12), 485-90. (e) Wright, C. I.; Geula, C.; Mesulam, M. M. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease. *Proc. Natl. Acad. Sci. U.S.A.* **1993**, *90*, 683-6. (f) de Serres, M.; Sherman, D.; Chesnut, W.; Merrill, B. M.; Viveros, O. H.; Diliberto, E. J., Jr. Proteolysis at the Secretase and Amyloidogenic Cleavage Sites of the β -Amyloid Precursor Protein by Acetylcholinesterase and Butyrylcholinesterase Using Model Peptide Substrates. *Cell. Mol. Neurobiol.* **1993**, *13* (3), 279-87.
- (8) (a) Nelson, R. B.; Siman, R. Clipsin, a Chymotrypsin-like Protease in Rat Brain Which Is Irreversibly Inhibited by Alpha-1-Antichymotrypsin. *J. Biol. Chem.* **1990**, *265*, 3836-43. (b) Potter, H.; Nelson, R. B.; Das, S.; Siman, R.; Kayyali, U. S.; Dressler, D. The involvement of proteases, protease inhibitors, and an acute phase response in Alzheimer's disease. *Ann. N.Y. Acad. Sci.* **1992**, *674*, 161-74. (c) Siman, R. Proteolytic mechanism for the neurodegeneration of Alzheimer's disease. *Ann. N.Y. Acad. Sci.* **1992**, *674*, 193-202. (d) Papastoitis, G.; Siman, R.; Scott, R.; Abraham, C. R. Identification of a metalloprotease from Alzheimer's disease brain able to degrade the β -amyloid precursor protein and generate amyloidogenic fragments. *Biochemistry* **1994**, *33* (1), 192-9.
- (9) (a) Moran, M. A.; Mufson, E. J.; Gomez-Ramos, P. Colocalization of Cholinesterases with β -amyloid protein in aged and Alzheimer's brains. *Acta Neuropathol.* **1993**, *85*, 362-9. (b) Shoji, M.; Golde, T. E.; Ghiso, J.; Cheung, T. T.; Estus, S.; Shaffer, L. M.; Cai, X.-D.; McKay, D. M.; Tintner, R.; Frangione, B.; Younkin, S. G. Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing. *Science* **1992**, *258*, 126-9. (c) Hensley, K.; Carney, J. M.; Mattson, M. P.; Aksenova, M.; Harris, M.; Wu, J. F.; Floyd, R. A.; Butterfield, D. A. A model for β -amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 3270-4.
- (10) (a) Vidaluc, J. L. Recent developments in acetylcholinesterase inhibitors: patent activity January 1993 to December 1994. *Exp. Opin. Ther. Patents* **1995**, *5* (4), 287-98. (b) Basic Patents: FR 91 011740, FR 91 06327, FR 91 09446. (c) Vidaluc, J. L.; Calmel, F.; Bigg, D.; Carilla, E.; Stenger, A.; Chopin, P.; Briley, M. Novel 2-(4-Piperidinyloxy)thioureas: Synthesis and Antiacetylcholinesterase Activity. *J. Med. Chem.* **1994**, *37*, 689-95.
- (11) (a) Yang, B.; Wright, J.; Eldefrawi, M. E.; Pou, S.; MacKerell, A. D., Jr. Conformational, Aqueous Solvation, and pKa Contributions to the Binding and Activity of Cocaine, WIN 32 065-2, and the WIN Vinyl Analog. *J. Am. Chem. Soc.* **1994**, *116*, 8722-32. (b) Tsai, R.-S.; Carrupt, P.-A.; Testa, B.; Gaillard, P.; El Tayar, N.; Högberg, T. Effects of Solvation on the ionization and Conformation of Raclopride and Other Antidopaminergic 6-Methoxysalicylamides: Insight into the Pharmacophore. *J. Med. Chem.* **1993**, *36*, 196-204. (c) Carrupt, P.-A.; Testa, B.; Bechalony, A.; El Tayar, N.; Descas, P.; Perrissoud, D. Morphine 6-Glucuronide and Morphine 3-Glucuronide as Molecular Chameleons with Unexpected Lipophilicity. *J. Med. Chem.* **1991**, *34*, 1272-5. (d) Bernards, C. M.; Hill, H. F. Physical and Chemical Properties of Drug Molecules Governing their Diffusion Through the Spinal Meninges. *Anesthesiology* **1992**, *77* (4), 750-6.
- (12) (a) Sugimoto, H.; Tsuchiya, Y.; Sugumi, H.; Higurashi, K.; Karibe, N.; Iimura, Y.; Sasaki, A.; Kawakami, Y.; Nakamura, T.; Araki, S.; Yamanishi, Y.; Yamatsu, K. Novel Piperidine Derivatives. Synthesis and Anti-Acetylcholinesterase Activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine Derivatives. *J. Med. Chem.* **1990**, *33*, 1880-7. (b) Sugimoto, H.; Tsuchiya, Y.; Sugumi, H.; Higurashi, K.; Karibe, N.; Iimura, Y.; Sasaki, A.; Araki, S.; Yamanishi, Y.; Yamatsu, K. Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-(2-phthalimidoethyl)piperidine and Related Derivatives. *ibid. J. Med. Chem.* **1991**, *35*, 4542-8. (c) Cardozo, M. G.; Iimura, Y.; Sugimoto, H.; Yamanishi, Y.; Hopfinger, A. J. QSAR Analyses of the Substituted Indanone and Benzylpiperidine Rings of a Series of Indanone-Benzylpiperidine Inhibitors of Acetylcholinesterase. *J. Med. Chem.* **1992**, *35*, 584-9. (d) Sugimoto, H.; Iimura, Y.; Yamanishi, Y.; Yamatsu, K. Synthesis and Anti-Acetylcholinesterase Activity of 1-Benzyl-4-[[5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E-2020) and Related Compounds. *Bioorg. Med. Chem. Lett.* **1992**, *2* (8), 871-6.
- (13) (a) Ishihara, Y.; Miyamoto, M.; Nakayama, T.; Goto, G. Central Cholinergic Agents. IV. Synthesis and Acetylcholinesterase Inhibitory Activities of w-[N-Ethyl-N-(phenylmethyl)amino]-1-phenyl-1-alkanones and Their Analogues with Partial Conformational Restriction. *Chem. Pharm. Bull.* **1993**, *41* (3), 529-38. (b) Ishihara, Y.; Miyamoto, M.; Yukimasa, H.; Goto, G. Central Cholinergic Agents. III. Synthesis of 2-Alkoxy-2,8-diazaspiro[4.5]decane-1,3-diones as Muscarinic Agonists. *Chem. Pharm. Bull.* **1992**, *40* (5), 1177-85. (c) Ishihara, Y.; Kato, K.; Goto, G. Central Cholinergic Agents. I. Potent Acetylcholinesterase Inhibitors, 2-[ω -[N-Alkyl-N-(ω -phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-diones, Based on a New Hypothesis of the Enzyme's Active Site. *Chem. Pharm. Bull.* **1991**, *39* (12), 3225-35. (d) Ishihara, Y.; Kato, K.; Goto, G. Central Cholinergic Agents. II. Synthesis and Acetylcholinesterase Inhibitory Activities of N-[ω -[N-Alkyl-N-(phenylmethyl)amino]alkyl]-3-arylpropanamides. *Chem. Pharm. Bull.* **1991**, *39* (12), 3236-43. (e) Yamamoto, Y.; Ishihara, Y.; Kuntz, D. Docking Analysis of a Series of Benzylamino Acetylcholinesterase Inhibitors with a Phthalimide, Benzoyl, or Indanone Moiety. *J. Med. Chem.* **1994**, *37*, 3141-53. (f) Ishihara, Y.; Hirai, K.; Miyamoto, M.; Goto, G. Central Cholinergic Agents. 6. Synthesis and Evaluation of 3-[1-(Phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanones and Their Analogs as Central Selective Acetylcholinesterase Inhibitors. *J. Med. Chem.* **1994**, *37*, 2292-9.
- (14) Calderon, S. N.; Newman, A. H.; Tortella, F. C. Novel 1-Phenylcycloalkane-carboxylic Acid Derivatives as Potential Anticonvulsant Agents. *J. Med. Chem.* **1991**, *34*, 3159-64.
- (15) Ellman, G. L.; Courtney, D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of Acetylcholinesterase Activity. *Biochem. Pharmacol.* **1961**, *7*, 88.
- (16) Thomsen, T.; Bickel, U.; Fischer, J. P.; Kewitz, H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. *Eur. J. Clin. Pharmacol.* **1990**, *39*, 603-5.
- (17) (a) Neurobiotech: Searching for solutions to Alzheimer's disease. *Biotechnol. Med. Technol.* **1990**, August 1st. (b) *Gen. Technol. News* **1989**, No. 11, 8. (c) Hutchings, H. H. Presented at the Innovative Biomedical Technology Conference, London, December 8, 1989.